Cold Spring Harbor Laboratory researchers have reported that a bespoke antisense oligonucleotide can disrupt alternative ...

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

The growth protein, MYC, was consistently found with RBM42, which spurs MYC production, in human pancreatic tumors. Above, microscopy for MYC (red) and RBM42 (green) in a representative pancreatic ...

Please provide your email address to receive an email when new articles are posted on . Inhibiting RMB42 disrupted production of Myc proteins in pancreatic cancer cells. This approach could curtail ...

Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.

A new review in Genes and Diseases explores the central role of MYC, a master regulatory protein, in the development and progression of cancer, spotlighting its potential as a multidimensional ...

The Krainer lab discovered a three-oncogene circuit that helps drive the aggressive progression of pancreatic ductal ...

Cambridge, MA, May 28 — Insilico Medicine (“Insilico”), in collaboration with research partner at Huadong Medicine Company, today announced the discovery of novel small-molecule inhibitors that ...

For decades, scientists have tried to stop cancer by disabling the mutated proteins that are found in tumors. But many cancers manage to overcome this and continue growing. Now, scientists think they ...